Evidence map›Paper›PMID 36348357›Full record

ReviewMolecular neurodegeneration2022

ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.

Ana-Caroline Raulin, Sydney V Doss, Zachary A Trottier, Tadafumi C Ikezu, Guojun Bu, Chia-Chen Liu

2 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Molecular neurodegeneration, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 455 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
455citing papers in PubMed, 4 pooled it
65.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05905822 completednot on this mapstarted 2023, after this paper: background citation

DIetary plAnt Extracts, Colonic MicrObes, and Apoe geNetics Interactions stuDy

TypeobservationalSponsorUniversity of East AngliaRan2023 to 2025Enrolled49ConditionsAlzheimer Disease
NCT07284316 phase2 / phase3active not recruitingnot on this mapstarted 2025, after this paper: background citation

Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance: A Randomized Clinical Trial

TypeinterventionalSponsorInstituto Mexicano del Seguro SocialRan2025 to 2027Enrolled100ConditionsCognitive Decline, Subjective Cognitive Impairment, Insulin ResistanceArmsTurmeric extract, Control: Placebo. 500mg gelatin in capsules 2 times a day
3 · Its place in the literature

Who cites it

455 citing papers in PubMed, 4 syntheses or guidelines pooled it, 623 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Unveiling the pathogenesis and therapeutic strategies of Alzheimer's disease through cuproptosis.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Cross-disease protein aggregate interactions in neurodegeneration: from molecular mechanisms to therapeutic strategies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  11. Article
  12. Prosocial helping behaviors attenuate accelerated cognitive decline driven by APOE ε4.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  13. Article
  14. New Genetic Associations Between Alzheimer's Disease and Its Key Risk Factors.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2026
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

395 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ana-Caroline Raulin *Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, 32224, Jacksonville, FL, USA.
Sydney V Doss *Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, 32224, Jacksonville, FL, USA.
Zachary A TrottierDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, 32224, Jacksonville, FL, USA.
Tadafumi C IkezuDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, 32224, Jacksonville, FL, USA.
Guojun BuDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, 32224, Jacksonville, FL, USA. Guojun.Bu@MolecularNeurodegeneration.org.
Chia-Chen LiuDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, 32224, Jacksonville, FL, USA. Liu.chiachen@mayo.edu.ORCID 0000-0001-7203-3926
Mayo Clinic in Florida · USJacksonville College · US

Funding

Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI Andrea Soranno · 2021 to 2026
$42.0M
Impact of ApoE2 on aging-related conditionsRF1AG057181 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2018 to 2018
$3.7M
ApoE pathway in cerebrovascular Aβ clearance in Alzheimer’s diseaseR37AG027924 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN · 2017 to 2020
$2.4M
NIA NIH HHS R37 AG027924NIA NIH HHS RF1 AG057181NIA NIH HHS U19 AG069701
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to extended lifespans. Among the increasing number of genetic risk factors identified, the apolipoprotein E (APOE) gene remains the strongest and most prevalent, impacting more than half of all AD cases. While the ε4 allele of the APOE gene significantly increases AD risk, the ε2 allele is protective relative to the common ε3 allele. These gene alleles encode three apoE protein isoforms that differ at two amino acid positions. The primary physiological function of apoE is to mediate lipid transport in the brain and periphery; however, additional functions of apoE in diverse biological functions have been recognized. Pathogenically, apoE seeds amyloid-β (Aβ) plaques in the brain with apoE4 driving earlier and more abundant amyloids. ApoE isoforms also have differential effects on multiple Aβ-related or Aβ-independent pathways. The complexity of apoE biology and pathobiology presents challenges to designing effective apoE-targeted therapeutic strategies. This review examines the key pathobiological pathways of apoE and related targeting strategies with a specific focus on the latest technological advances and tools.

Indexed as

Alzheimer DiseaseAllelesAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins EHumansPlaque, AmyloidAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins E

Identifiers

PMID36348357
PMCPMC9644639
OpenAlexW4308572221

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.